Home › Companies › DENALI THERAPEUTICS INC. › 2024-2025

DENALI THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and DENALI THERAPEUTICS INC.’s Form 8-K, filed 2025-06-03 (Item 5.07 on EDGAR). Page generated 04 October 2026.

9Reported items
250Asset managers
1,631Fund votes
2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore DENALI THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by DENALI THERAPEUTICS INC.

These tallies are DENALI THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

DENALI THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Julian Baker	98,032,346	--	--	22,859,131	10,176,385	Majority: yes
Elect Director: Peter Klein	106,248,604	--	--	14,642,873	10,176,385	Majority: yes
Elect Director: Steve Krognes	64,815,389	--	--	56,076,088	10,176,385	Majority: yes

Source: DENALI THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-03 — read the filing on EDGAR.

How asset managers voted at the DENALI THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 250 asset managers that disclosed a DENALI THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of DENALI THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory Vote to Ratify Named Executive Officers' Compensation

COMPENSATION

90% fund support · no official result

FOR 90%10%

The 239 asset managers below cast 90% of the shares they voted on this item FOR (128,504,041 for, 14,548,489 against).

FOR: 128,504,041 (89.8%)AGAINST: 14,548,489 (10.2%)ABSTAIN: 39,642 (0.0%)NOT VOTED: 4,363 (0.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	25,625,170	0	For
Fidelity	15,479,974	0	For
Wellington	12,223,224	0	For
T. Rowe Price	9,375,917	0	For
BlackRock	8,654,799	0	For
BAILLIE GIFFORD & CO LTD	8,466,903	0	For
State Street	5,444,898	0	For
Temasek Holdings (Private) Ltd	5,355,832	0	For
Capital Research Global Investors	0	4,542,711	Against
AllianceBernstein	3,956,946	0	For
UBS	0	3,798,232	Against
BAKER BROS. ADVISORS LP	3,731,695	0	For
Capital Group	0	3,462,006	Against
BAILLIE GIFFORD OVERSEAS LTD	3,047,937	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,988,636	0	For
Charles Schwab	2,049,184	0	For
Aberdeen	1,519,630	0	For
Camber Capital Management LP	1,250,000	0	For
MARSHALL WACE, LLP	1,114,693	0	For
Dimensional	1,057,033	0	For
NEW ECONOMY FUND	0	1,024,429	Against
Fisher Asset Management, LLC	992,536	0	For
Artisan	982,702	0	For
Casdin Capital, LLC	890,000	0	For
Candriam S.C.A.	0	858,162	Against

Showing the 25 largest of 239 asset managers. See all 239 in the interactive database.

2. ELECTION OF DIRECTORS: Julian Baker

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%

FOR: 98,032,346WITHHELD: 22,859,131

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julian Baker”): 98,032,346 for, 22,859,131 withheld, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,251,258 outstanding shares: 67% for, 16% withheld (83% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (44,219,761 for, 0 against).

FOR 77%ABSTAIN 23%

FOR: 44,219,761 (76.9%)ABSTAIN: 13,297,756 (23.1%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Julian Baker” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	14,510,350	10,728,901	For
Fidelity	8,000,813	0	For
BlackRock	4,793,387	0	For
T. Rowe Price	4,069,138	0	For
Capital Group	3,462,006	0	For
State Street	1,502,864	58	For
AllianceBernstein	0	1,057,610	Abstain
NEW ECONOMY FUND	1,024,429	0	For
Charles Schwab	1,015,514	0	For
Dimensional	779,940	0	For
Aberdeen	759,815	0	For
Principal	506,100	209,758	For
AB DISCOVERY GROWTH FUND, INC.	0	614,855	Abstain
Equitable	231,406	370,890	Abstain
BNY Mellon	446,002	0	For
Artisan	423,041	0	For
Yiheng Capital Management, L.P.	318,239	0	For
TIAA	316,575	0	For
Brighthouse	170,896	48,436	For
QUANTITATIVE MASTER SERIES LLC	211,929	0	For
Lincoln Financial	155,863	0	For
American Century	136,150	0	For
New York Life	91,344	26,144	For
Jackson National	111,797	0	For
ALPS ETF Trust	111,375	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

3. ELECTION OF DIRECTORS: Peter Klein

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 106,248,604WITHHELD: 14,642,873

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Klein”): 106,248,604 for, 14,642,873 withheld, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,251,258 outstanding shares: 73% for, 10% withheld (83% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (52,697,344 for, 0 against).

FOR 92%8%

FOR: 52,697,344 (91.6%)ABSTAIN: 4,820,173 (8.4%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Peter Klein” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	25,239,251	0	For
Fidelity	8,000,813	0	For
BlackRock	4,793,387	0	For
T. Rowe Price	4,069,138	0	For
Capital Group	3,462,006	0	For
State Street	5,135	1,497,787	Abstain
AllianceBernstein	0	1,057,610	Abstain
NEW ECONOMY FUND	1,024,429	0	For
Charles Schwab	1,015,514	0	For
Dimensional	0	779,940	Abstain
Aberdeen	759,815	0	For
Principal	506,374	209,484	For
AB DISCOVERY GROWTH FUND, INC.	0	614,855	Abstain
Equitable	231,406	370,890	Abstain
BNY Mellon	446,002	0	For
Artisan	423,041	0	For
Yiheng Capital Management, L.P.	318,239	0	For
TIAA	316,575	0	For
Brighthouse	181,037	38,295	For
QUANTITATIVE MASTER SERIES LLC	211,929	0	For
Lincoln Financial	55,931	99,932	Abstain
American Century	136,150	0	For
New York Life	117,488	0	For
Jackson National	86,251	25,546	For
ALPS ETF Trust	111,375	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

4. ELECTION OF DIRECTORS: Steve Krognes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

53.6% Majority: yes · of votes cast

FOR 53.6%WITHHELD 46.4%

FOR: 64,815,389WITHHELD: 56,076,088

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Steve Krognes”): 64,815,389 for, 56,076,088 withheld, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,251,258 outstanding shares: 45% for, 39% withheld (83% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (21,924,797 for, 0 against).

FOR 38%ABSTAIN 62%

FOR: 21,924,797 (38.1%)ABSTAIN: 35,592,720 (61.9%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Steve Krognes” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	13,755,701	11,483,550	For
Fidelity	0	8,000,813	Abstain
BlackRock	0	4,793,387	Abstain
T. Rowe Price	0	4,069,138	Abstain
Capital Group	3,462,006	0	For
State Street	3,472	1,499,450	Abstain
AllianceBernstein	1,057,610	0	For
NEW ECONOMY FUND	1,024,429	0	For
Charles Schwab	0	1,015,514	Abstain
Dimensional	0	779,940	Abstain
Aberdeen	0	759,815	Abstain
Principal	209,758	506,100	Abstain
AB DISCOVERY GROWTH FUND, INC.	614,855	0	For
Equitable	370,890	231,406	For
BNY Mellon	446,002	0	For
Artisan	423,041	0	For
Yiheng Capital Management, L.P.	318,239	0	For
TIAA	0	316,575	Abstain
Brighthouse	0	219,332	Abstain
QUANTITATIVE MASTER SERIES LLC	0	211,929	Abstain
Lincoln Financial	0	155,863	Abstain
American Century	0	136,150	Abstain
New York Life	26,144	91,344	Abstain
Jackson National	2,107	109,690	Abstain
ALPS ETF Trust	0	111,375	Abstain

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.8%

The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (57,348,070 for, 37,235 against).

FOR: 57,348,070 (99.9%)AGAINST: 37,235 (0.1%)ABSTAIN: 38,295 (0.1%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	25,239,251	0	0	For
Fidelity	8,000,813	0	0	For
BlackRock	4,793,387	0	0	For
T. Rowe Price	4,069,138	0	0	For
Capital Group	3,462,006	0	0	For
State Street	1,502,864	58	0	For
AllianceBernstein	1,057,610	0	0	For
NEW ECONOMY FUND	1,024,429	0	0	For
Charles Schwab	1,015,514	0	0	For
Dimensional	779,940	0	0	For
Aberdeen	759,815	0	0	For
Principal	715,858	0	0	For
AB DISCOVERY GROWTH FUND, INC.	614,855	0	0	For
Equitable	602,296	0	0	For
BNY Mellon	446,002	0	0	For
Artisan	423,041	0	0	For
Yiheng Capital Management, L.P.	318,239	0	0	For
TIAA	316,575	0	0	For
Brighthouse	181,037	0	38,295	For
QUANTITATIVE MASTER SERIES LLC	211,929	0	0	For
Lincoln Financial	155,863	0	0	For
American Century	136,150	0	0	For
New York Life	117,488	0	0	For
Jackson National	111,797	0	0	For
ALPS ETF Trust	111,375	0	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

6. 14A Executive Compensation Advisory vote on executive compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (296,938 for, 0 against).

FOR: 296,938 (100.0%)

Largest asset managers voting on “14A Executive Compensation Advisory vote on executive compensation” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Pier Capital, LLC	214,894	For
RBB FUND, INC.	45,205	For
Dunham Funds	36,839	For

7. Ratify Appointment of Independent Auditors Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (82,044 for, 0 against).

FOR: 82,044 (100.0%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors Ratification of the appointment of Ernst & Young LLP as our indepen” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
RBB FUND, INC.	45,205	0	0	0	For
Dunham Funds	36,839	0	0	0	For

8. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (11,873 for, 0 against).

FOR: 11,873 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
VALUED ADVISERS TRUST	11,835	0	0	0	For
UNIFIED SERIES TRUST	38	0	0	0	For

9. Advisory vote on executive compensation.

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (158,500 for, 0 against).

FOR: 158,500 (100.0%)

Largest asset managers voting on “Advisory vote on executive compensation.” at DENALI THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
DAFNA Capital Management LLC	158,500	0	0	0	For
MASTERS CAPITAL MANAGEMENT LLC	0	0	0	0	--

Largest DENALI THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of DENALI THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 145,251,258 shares outstanding at the time of that meeting.

Top DENALI THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	17.64%
2	Fidelity	10.66%
3	Wellington	8.42%
4	T. Rowe Price	6.45%
5	BlackRock	5.96%
6	BAILLIE GIFFORD & CO LTD	5.83%
7	State Street	3.75%
8	Temasek Holdings (Private) Ltd	3.69%
9	Capital Research Global Investors	3.13%
10	AllianceBernstein	2.72%

Reported DENALI THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

DENALI THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	9.52%	13F
BAILLIE GIFFORD & CO	8.48%	13G
Vanguard Group	8.12%	13F
Wellington Management	7.86%	13F
Wellington	7.39%	DEF14A
FMR LLC	6.98%	DEF14A
Julian C. Baker	5.12%	DEF14A
FMR (Fidelity)	5.10%	13F
Ryan J. Watts, Ph.D.	3.13%	DEF14A
State Street	3.07%	13F

Percentages above are of 145,251,258 shares outstanding, as reported by DENALI THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DENALI THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At DENALI THERAPEUTICS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 250 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,631 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. DENALI THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Advisory Vote to Ratify Named Executive Officers' Compensation — the reporting funds cast 90% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

DENALI THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.